The latest update is out from NewAmsterdam Pharma Company ( (NAMS) ).
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
NewAmsterdam Pharma has announced promising results from its Phase 3 TANDEM clinical trial, showcasing the effectiveness of a fixed-dose combination of obicetrapib and ezetimibe in significantly reducing LDL-C levels in patients with cardiovascular disease or high-risk factors. The trial met its primary endpoints, demonstrating a 50% reduction in LDL-C compared to placebo, and showed that over 70% of patients achieved LDL-C levels below 55 mg/dL. The combination treatment was well tolerated, aligning with past safety data, and is expected to support global regulatory filings.
For detailed information about NAMS stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Nvidia Stock Could Take a Beating from Supply Snags on Blackwell Chips
- ‘This Is Just Pure Hype,’ Says Top Investor About Tesla Stock
- Will Palantir Stock Crash to $28? Jefferies Sounds the Alarm
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
